查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1404654

再生医学市场规模、份额、趋势分析报告：按产品、治疗类别、地区、细分市场预测，2024-2030

Regenerative Medicine Market Size, Share & Trends Analysis Report By Product, By Therapeutic Category, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 230 Pages | 商品交期: 2-10个工作天内

价格

再生医学市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计2024年至2030年全球再生医学市场规模将以16.79%的复合年增长率扩张，2030年将达到900.1亿美元。

强大的产品线是再生医学市场的关键驱动因素之一。本公司大力投资研发，利用最新技术升级产品，满足客户未满足的需求。

此外，对疾病治疗疗法的需求不断增长，促使公司专注于加速在基因组层面上针对疾病原因的基因疗法的研究和开发。根据PhRMA发表的资料，美国处于管道计画（I-III期试验）的细胞和基因治疗药物数量从2018年的289个增加到2019年的362个。这是一年内成长了 25%。该领域的持续进步可能会进一步推动再生医学的需求。

干细胞、组织工程和奈米技术等技术的进步使再生医学成为一个高度跨学科的领域。干细胞是未分化的细胞，具有修復和再生其他细胞（如软骨、肌腱、韧带、肌肉和骨骼）的能力。 2021 年 7 月，BlueRock Therapeutics 的 DA01 获得 FDA核准，DA01 是一种多功能细胞衍生的多巴胺能神经元疗法，用于治疗进行性帕金森氏症。此次核准预计将扩大该公司的产品阵容。

几家主要企业正在采取新产品开发和策略联盟等策略性倡议，为再生医学市场的成长做出贡献。例如，2021年11月，Astellas製药与Pantherna Therapeutics GmbH签署了一项协议，研究基于mRNA的再生医学。该计划利用Astellas的药物药物研发能力和 Pantherna 的尖端 mRNA 平台来推动研究开发新项目。此外，2021 年 5 月，拜耳股份公司与 Senti Bio 建立合作伙伴关係，开发结合遗传电路的再生医学细胞疗法。

再生医学市场报告亮点

  • 由于社会高龄化和与老龄化的疾病增加，治疗药物领域占据了再生医学市场的最大份额。
  • 干细胞和组织再生疗法临床试验的增加以及再生疗法需求的增加预计将对市场成长产生积极影响。
  • 由于研发方面的巨额投资以及干细胞库的扩散，基于干细胞和前驱细胞细胞的治疗方法有望显着增长。
  • 2023年的市场规模以北美为主，因为有许多研究机构和大学致力于干细胞治疗方法的研发。
  • 由于细胞技术在医疗保健行业的快速采用，预计亚太地区在未来几年将经历最快的成长。
  • 从治疗类别来看，随着全球癌症患者数量的增加，对更好解决方案的需求增加，肿瘤学将在 2023 年占据该领域的主导地位。强劲的管道增加正在推动市场成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势及展望
  • 市场动态
    • 拥有强大的产品线和大量的临床试验
    • 再生医学的高经济效益
    • 基因治疗在再生医学的新应用
    • 增加政府和私人资金支持再生医学的发展
    • 再生医学的技术进步（干细胞、组织工程、奈米技术）
    • 加强策略伙伴关係，加速再生医学的开发与商业化
    • 慢性病、遗传疾病、退化性疾病疾病以及骨关节疾病盛行率的上升将增加对再生治疗的需求
  • 市场抑制因素分析
    • 昂贵的治疗费用
    • 与干细胞、组织工程和再生医学相关的监管问题
  • 营商环境分析
    • PESTEL分析
    • 波特五力分析
    • COVID-19感染疾病的影响分析

第四章 产品经营分析

  • 全球再生医学市场：产品波动分析
  • 疗法
    • 治疗药物市场，2018-2030
    • 初代细胞治疗方法
    • 基于干细胞和前驱细胞的治疗方法
    • 基于细胞的免疫疗法
    • 基因治疗
  • 工具
    • 工具市场，2018-2030
  • 银行
    • 银行市场，2018-2030
  • 服务
    • 服务市场，2018-2030

第五章治疗类别业务分析

  • 全球再生医学市场：治疗类别变化分析
  • 皮肤科
  • 肌肉骨骼系统
  • 免疫学和发炎
  • 肿瘤学
  • 心血管
  • 眼科
  • 其他的

第六章 区域业务分析

  • 2022年及2030年全球再生医学市场占有率（按地区）
  • 北美洲
    • 北美再生医学市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲再生医学市场，2018-2030
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太再生医学市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲再生医学市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 中东和非洲再生医学市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争形势

  • 公司分类
  • 策略规划
  • 2022 年公司市场/职位占有率分析
  • 公司简介/名单
    • AstraZeneca plc.
    • F. Hoffmann-La Roche Ltd.
    • Integra Lifesciences Corp.
    • Astellas Pharma, Inc.
    • Cook Biotech, Inc.
    • Bayer AG
    • Pfizer, Inc.
    • Merck KGaA
    • Abbott
    • Vericel Corp.
    • Novartis AG
    • GlaxoSmithKline
Product Code: GVR-1-68038-952-4

Regenerative Medicine Market Growth & Trends:

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights:

  • The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
  • The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
  • Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
  • North America dominated the market in 2023 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
  • Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
  • By therapeutic category, the oncology segment dominated the segment in 2023 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Information Procurement
    • 1.3.1. Primary Others
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Market Model
  • 1.7. Objectives
    • 1.7.1. Objective 1
    • 1.7.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Presence of a strong pipeline and a large number of clinical trials
    • 3.3.2. High economic impact of regenerative medicine
    • 3.3.3. Emerging applications of gene therapy in regenerative medicine
    • 3.3.4. Increasing government & private funding to support the development of regenerative medicine
    • 3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
    • 3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
    • 3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
  • 3.4. Market Restraint Analysis
    • 3.4.1. High cost of treatment
    • 3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Global Regenerative Medicine Market: Product Movement Analysis
  • 4.2. Therapeutics
    • 4.2.1. Therapeutics Market, 2018 - 2030 (USD Million)
    • 4.2.2. Primary Cell-Based Therapeutics
      • 4.2.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Dermatology
      • 4.2.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Musculoskeletal
      • 4.2.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
      • 4.2.2.4. Surgical
      • 4.2.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
      • 4.2.2.5. Dental
      • 4.2.2.5.1. Dental Market, 2018 - 2030 (USD Million)
      • 4.2.2.6. Others
      • 4.2.2.6.1. Others Market, 2018 - 2030 (USD Million)
    • 4.2.3. Stem Cell & Progenitor Cell-based therapeutics
      • 4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
      • 4.2.3.2. Autologous
      • 4.2.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
      • 4.2.3.3. Allogenic
      • 4.2.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
      • 4.2.3.4. Others
      • 4.2.3.5. Others Market, 2018 - 2030 (USD Million)
    • 4.2.4. Cell-based Immunotherapies
      • 4.2.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
    • 4.2.5. Gene Therapies
      • 4.2.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
  • 4.3. Tools
    • 4.3.1. Tools Market, 2018 - 2030 (USD Million)
  • 4.4. Banks
    • 4.4.1. Banks Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Category Business Analysis

  • 5.1. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
  • 5.2. Dermatology
    • 5.2.1. Dermatology Market, 2018 - 2030 (USD Million)
  • 5.3. Musculoskeletal
    • 5.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 5.4. Immunology & Inflammation
    • 5.4.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.6. Cardiovascular
    • 5.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
  • 5.7. Ophthalmology
    • 5.7.1. Ophthalmology Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Global Regenerative Medicine Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Target Disease Prevalence
      • 6.2.2.5. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Target Disease Prevalence
      • 6.2.3.5. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Target Disease Prevalence
      • 6.3.2.5. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Target Disease Prevalence
      • 6.3.3.5. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Target Disease Prevalence
      • 6.3.4.5. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Target Disease Prevalence
      • 6.3.5.5. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Target Disease Prevalence
      • 6.3.6.5. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Target Disease Prevalence
      • 6.3.7.5. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Target Disease Prevalence
      • 6.3.8.5. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Target Disease Prevalence
      • 6.3.9.5. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Target Disease Prevalence
      • 6.4.2.5. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Target Disease Prevalence
      • 6.4.3.5. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Target Disease Prevalence
      • 6.4.4.5. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Target Disease Prevalence
      • 6.4.5.5. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Target Disease Prevalence
      • 6.4.6.5. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Target Disease Prevalence
      • 6.4.7.5. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Target Disease Prevalence
      • 6.5.2.5. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Target Disease Prevalence
      • 6.5.3.5. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.4. Argentina
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Target Disease Prevalence
      • 6.5.4.5. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Target Disease Prevalence
      • 6.6.2.5. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Target Disease Prevalence
      • 6.6.3.5. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Target Disease Prevalence
      • 6.6.4.5. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Target Disease Prevalence
      • 6.6.5.5. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market/Position Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. AstraZeneca plc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Integra Lifesciences Corp.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Astellas Pharma, Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Cook Biotech, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Bayer AG
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Pfizer, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Merck KGaA
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Abbott
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Vericel Corp.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Novartis AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. GlaxoSmithKline
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 5 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 7 North America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 8 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 10 Canada Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 11 Canada Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 12 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 15 Germany Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 16 Germany Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 17 U.K. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 18 U.K. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 19 France Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 20 France Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 21 Italy Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 22 Italy Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 23 Spain Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 24 Spain Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 25 Denmark Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 27 Norway Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 28 Norway Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 29 Sweden Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 30 Sweden Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 34 China Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 35 China Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 36 Japan Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 37 Japan Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 38 India Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 39 India Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 40 Australia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 41 Australia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 42 South Korea Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 43 South Korea Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 44 Thailand Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 45 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 46 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 49 Brazil Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 50 Brazil Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 51 Mexico Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 52 Mexico Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 53 Argentina Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 54 Argentina Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 58 South Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 59 South Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 62 UAE Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 63 UAE Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 66 Participant's Overview
  • Table 67 Financial Performance
  • Table 68 Key Companies Undergoing Expansions
  • Table 69 Key Companies Undergoing Acquisitions
  • Table 70 Key Companies Undergoing Collaborations
  • Table 71 Key Companies Launching New Products/Services
  • Table 72 Key Companies Undergoing Partnerships
  • Table 73 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market Others process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary Others pattern
  • Fig. 4 Market Others approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2023 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 16 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 17 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 18 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 19 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 20 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 21 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 22 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 23 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 25 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 26 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
  • Fig. 27 Global gene therapies market, 2018 - 2030 (USD Million)
  • Fig. 28 Global regenerative medicines tools, 2018 - 2030 (USD Million)
  • Fig. 29 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
  • Fig. 30 Global regenerative medicine services market, 2018 - 2030 (USD Million)
  • Fig. 31 Regenerative medicine market: Therapeutic category outlook and key takeaways
  • Fig. 32 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
  • Fig. 33 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 34 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 35 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 36 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 37 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 38 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Global other therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 40 Global Regenerative Medicine Market: Regional outlook and key takeaways
  • Fig. 41 North America Regenerative Medicine Market, 2018 - 2030 (USD million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. Regenerative Medicine Market, 2018 - 2030 (USD million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada Regenerative Medicine Market, 2018 - 2030 (USD million)
  • Fig. 46 Europe Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 U.K. key country dynamics
  • Fig. 52 U.K. Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Italy key country dynamics
  • Fig. 54 Italy Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Spain key country dynamics
  • Fig. 56 Spain Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark key country dynamics
  • Fig. 58 Denmark Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Sweden key country dynamics
  • Fig. 60 Sweden Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Norway key country dynamics
  • Fig. 62 Norway Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Asia-Pacific Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 China key country dynamics
  • Fig. 65 China Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 South Korea key country dynamics
  • Fig. 69 South Korea Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico key country dynamics
  • Fig. 80 Mexico Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 MEA Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Market participant categorization
  • Fig. 93 Regenerative Medicine Market share analysis, 2023
  • Fig. 94 Strategy framework